•
Mar 31, 2021

Chemed Q1 2021 Earnings Report

Chemed's financial performance in Q1 2021 was reported, featuring revenue growth and increased EPS, alongside segment-specific results for VITAS and Roto-Rooter.

Key Takeaways

Chemed Corporation reported a 2.2% increase in revenue to $527 million for Q1 2021. GAAP Diluted EPS increased by 18.6% to $4.01, and Adjusted Diluted EPS rose by 20.7% to $4.44. The VITAS segment experienced a revenue decline, while Roto-Rooter saw significant revenue growth.

Chemed's revenue increased by 2.2% to $527 million.

GAAP Diluted EPS increased by 18.6% to $4.01.

Roto-Rooter's revenue increased by 18.9% to $212 million.

VITAS Healthcare's net patient revenue decreased by 6.5% to $316 million.

Total Revenue
$527M
Previous year: $516M
+2.2%
EPS
$4.44
Previous year: $3.68
+20.7%
Admissions
18.14K
Previous year: 18.6K
-2.5%
Average Daily Census
18.05K
Previous year: 19.22K
-6.1%
Gross Profit
$187M
Previous year: $164M
+13.9%
Cash and Equivalents
$210M
Previous year: $29M
+624.7%
Free Cash Flow
$89M
Previous year: $69.4M
+28.2%
Total Assets
$1.46B
Previous year: $1.28B
+14.1%

Chemed

Chemed

Chemed Revenue by Segment

Chemed Revenue by Geographic Location

Forward Guidance

Management anticipates providing updated 2021 earnings guidance in July 2021 as part of the June 30, 2021, earnings press release.

Revenue & Expenses

Visualization of income flow from segment revenue to net income